New β-lactamases: A paradigm for the rapid response of bacterial evolution in the clinical setting

Antimicrobial resistance; Carbapenemases; Evolution; Extended-spectrum β-lactamases; Gram-negative bacteria; AmpC beta lactamases; AmpC beta-lactamases; Enterobacteriaceae; Review; Bacteria; Bacterial Proteins; Carbapenems; Cephalosporins; Evolution, Molecular; Mutation

Abstract :

[en] Production of β-lactamases is one of the most common mechanisms of bacterial resistance to β-lactam antibiotics. In the clinical setting, the introduction of new classes of β-lactams has invariably been followed by the emergence of new β-lactamases capable of degrading them, as a paradigmatic example of rapid bacterial evolution under a rapidly changing selective environment. The scope of this article is to provide an overview on the recent evolution of β-lactamase-mediated resistance among bacterial pathogens. Focus is on the mechanisms of evolution and dissemination of enzymes of greater clinical impact, including the extended-spectrum β-lactamases, the AmpC-type β-lactamases and the carbapenemases, which are currently responsible for emerging resistance to the most recent and powerful β-lactams (the expanded-spectrum cephalosporins and the carbapenems) among major Gram-negative pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter. © 2006 Future Medicine Ltd.

Disciplines :

Microbiology

Author, co-author :

Rossolini, G. M.; University of Siena, Department of Molecular Biology, Section of Microbiology, Policlinico Santa Maria alle Scotte, Siena, 53100, Italy

Docquier, Jean-Denis ; Université de Liège - ULiège > Département des sciences de la vie > Centre d'ingénierie des protéines

Language :

English

Title :

New β-lactamases: A paradigm for the rapid response of bacterial evolution in the clinical setting

Publication date :

2006

Journal title :

Future Microbiology

ISSN :

1746-0913

eISSN :

1746-0921

Publisher :

Future Medicine Ltd.

Volume :

Issue :

Pages :

295-308

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 25 November 2020

Statistics

Number of views

37 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Medeiros AA: Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24(Suppl. 1), S19-S45 (1997).
Matagne A, Dubus A, Galleni M, Frere JM: The β-lactamase cycle: a tale of selective pressure and bacterial ingenuity. Nat. Prod. Rep. 16(1), 1-19 (1999).
Jacoby GA, Munoz-Price LS: The new β-lactamases. N. Engl. J. Med. 352(4), 380-391 (2005).
Livermore DM, Woodford N: The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14(9), 413-420 (2006).
Paterson DL: Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control 34(5 Suppl. 1), S20-S28 (2006).
Thomson JM, Bonomo RA: The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril! Curr. Opin. Microbiol. 8(5), 518-524 (2005).
Bozdogan B, Tristram S, Appelbaum PC: Combination of altered PBPs and expression of cloned extended-spectrum β-lactamases confers cefotaxime resistance in Haemophilus influenzae. J. Antimicrob. Chemother. 57(4), 747-749 (2006).
Rice LB: Antimicrobial resistance in Gram-positive bacteria. Am. J. Med. 119(6 Suppl. 1), S11-S19 (2006).
Appelbaum PC: Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. Dis. 34(12), 1613-1620 (2002).
Styers D, Sheehan DJ, Hogan P, Sahm DF: Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob. 5, 2 (2006).
Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11(6), 315-317 (1983).
Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J: Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 8554, 302-306 (1987).
Paterson DL, Bonomo RA: Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657-686 (2005).
Winokur PL, Canton R, Casellas JM, Legakis N: Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin. Infect. Dis. 32(Suppl. 2), S94-S103 (2001).
Edelstein M, Pimkin M, Palagin I, Edelstein I, Stratchounski L: Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob. Agents Chemother. 47(12), 3724-3732 (2003).
Bouchillon SK, Johnson BM, Hoban DJ et al.: Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int. J. Antimicrob. Agents 24(2), 119-124 (2004).
Hirakata Y, Matsuda J, Miyazaki Y et al.: Regional variation in the prevalence of extended-spectrum β-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn. Microbiol. Infect. Dis. 52(4), 323-329 (2005).
Livermore DM: β-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8(4), 557-584 (1995).
Knox JR: Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39(12), 2593-2601 (1995).
Bradford PA: Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14(4), 933-951 (2001).
Raquet X, Vanhove M, Lamotte-Brasseur J, Goussard S, Courvalin P, Frere JM: Stability of TEM β-lactamase mutants hydrolyzing third generation cephalosporins. Proteins 23(1), 63-72 (1995).
Wang X, Minasov G, Shoichet BK: Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320(1), 85-95 (2002).
Huang W, Palzkill T: A natural polymorphism in β-lactamase is a global suppressor. Proc. Natl Acad. Sci. USA 94(16), 8801-8806 (1997).
Poyart C, Mugnier P, Quesne G, Berche P, Trieu-Cuot P: A novel extended-spectrum TEM-type β-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 42(1), 108-113 (1998).
De Champs C, Monne C, Bonnet R et al.: New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates. Antimicrob. Agents Chemother. 45(4), 1278-1280 (2001).
Perilli M, Segatore B, De Massis MR et al.: TEM-72, a new extended-spectrum β-lactamase detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrob. Agents Chemother. 44(9), 2537-2539 (2000).
Pai H, Lyu S, Lee JH et al.: Survey of extended-spectrum β-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea. J. Clin. Microbiol. 37(6), 1758-1763 (1999).
Perilli M, Dell'Amico E, Segatore B et al.: Molecular characterization of extended-spectrum β-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J. Clin. Microbiol. 40(2), 611-614 (2002).
Tzouvelekis LS, Bonomo RA: SHV-type β-lactamases. Curr. Pharm. Des. 5(11), 847-864 (1999).
Nukaga M, Mayama K, Hujer AM, Bonomo RA, Knox JR: Ultrahigh resolution structure of a class A β-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol. 328(1), 289-301 (2003).
Majiduddin FK, Palzkill T: An analysis of why highly similar enzymes evolve differently. Genetics 163(2), 457-466 (2003).
Bonnet R: Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48(1), 1-14 (2004).
Livermore DM, Hawkey PM: CTX-M: changing the face of ESBLs in the UK. J. Antimicrob. Chemother. 56(3), 451-454 (2005).
Hernandez JR, Martinez-Martinez L, Canton R, Coque TM, Pascual A: Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob. Agents Chemother. 49(5), 2122-2125 (2005).
Luzzaro F, Mezzatesta M, Mugnaioli C et al.: Trends in production of extended-spectrum β-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J. Clin. Microbiol. 44(5), 1659-1664 (2006).
Poirel L, Kampfer P, Nordmann P: Chromosome-encoded Ambler class A β-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 46(12), 4038-4040 (2002).
Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R, Philippon A: β-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob. Agents Chemother. 46(9), 3045-3049 (2002).
Rodriguez MM, Power P, Radice M et al.: Chromosome-encoded CTX-M-3 from Kluyvera ascorbata: a possible origin of plasmid-borne CTX-M-1-derived cefotaximases. Antimicrob. Agents Chemother. 48(12), 4895-4897 (2004).
Olson AB, Silverman M, Boyd DA et al.: Identification of a progenitor of the CTX-M-9 group of extended-spectrum β-lactamases from Kluyvera georgiana isolated in Guyana. Antimicrob. Agents Chemother. 49(5), 2112-2115 (2005).
Abbott SL: Klebsiella, Enterobacter, Citrobacter, Serratia, Plesiomonas, and other Enterobacteriaceae. In: Manual of Clinical Microbiology (8th Edition). Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (Eds). ASM Press, Washington DC, USA, 684-700 (2003).
Poirel L, Lartigue MF, Decousser JW, Nordmann P: ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli. Antimicrob. Agents Chemother. 49(1), 447-450 (2005).
Toleman MA, Bennett PM, Walsh TR: ISCR elements: novel gene-capturing systems of the 21st century? Microbiol. Mol. Biol. Rev. 70(2), 296-316 (2006).
Oliver A, Coque TM, Alonso D, Valverde A, Baquero F, Canton R: CTX-M-10 linked to a phage-related element is widely disseminated among Enterobacteriaceae in a Spanish hospital. Antimicrob. Agents Chemother. 49(4), 1567-1571 (2005).
Ibuka AS, Ishii Y, Galleni M et al.: Crystal structure of extended-spectrum β-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry 42(36), 10634-10643 (2003).
Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R: Atomic resolution structures of CTX-M β-lactamases: extended spectrum activities from increased mobility and decreased stability. J. Mol. Biol. 348(2), 349-362 (2005).
Kimura S, Ishiguro M, Ishii Y, Alba J, Yamaguchi K: Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis. Antimicrob. Agents Chemother. 48(5), 1454-1460 (2004).
Hanson ND: AmpC β-lactamases: what do we need to know for the future? J. Antimicrob. Chemother. 52(1), 2-4 (2003).
Philippon A, Arlet G, Jacoby GA: Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46(1), 1-11 (2002).
Miriagou V, Tzouvelekis LS, Villa L et al.: CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid. Antimicrob. Agents Chemother. 48(8), 3172-3174 (2004).
Kang MS, Besser TE, Call DR: Variability in the region downstream of the blaCMY-2 β-lactamase gene in Escherichia coli and Salmonella enterica plasmids. Antimicrob. Agents Chemother. 50(4), 1590-1593 (2006).
Verdet C, Benzerara Y, Gautier V, Adam O, Ould-Hocine Z, Arlet G: Emergence of DHA-1-producing Klebsiella spp. in the Parisian region: genetic organization of the ampC and ampR genes originating from Morganella morganii. Antimicrob. Agents Chemother. 50(2), 607-617 (2006).
Wachino J, Kurokawa H, Suzuki S et al.: Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob. Agents Chemother. 50(2), 534-541 (2006).
Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P: Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob. Agents Chemother. 48(3), 716-720 (2004).
Doi Y, Wachino J, Ishiguro M et al.: Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob. Agents Chemother. 48(7), 2652-2658 (2004).
Barnaud G, Benzerara Y, Gravisse J et al.: Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob. Agents Chemother. 48(3), 1040-1042 (2004).
Barnaud G, Labia R, Raskine L, Sanson-Le Pors MJ, Philippon A, Arlet G: Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol. Lett. 195(2), 185-190 (2001).
Kim JY, Jung HI, An YJ et al.: Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol. Microbiol. 60(4), 907-916 (2006).
Clissold SP, Todd PA, Campoli-Richards DM: Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 33(3), 183-241 (1987).
Livermore DM, Woodford N: Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. 3(5), 489-495 (2000).
Nordmann P, Poirel L: Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8(6), 321-331 (2002).
Livermore DM: Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47(3), 247-250 (2001).
Poirel L, Heritier C, Podglajen I, Sougakoff W, Gutmann L, Nordmann P: Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV β-lactamase that compromises the efficacy of imipenem. Antimicrob. Agents Chemother. 47(2), 755-758 (2003).
Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P: GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob. Agents Chemother. 45(9), 2598-2603 (2001).
Aubron C, Poirel L, Ash RJ, Nordmann P: Carbapenemase-producing Enterobacteriaceae, US rivers. Emerg. Infect. Dis. 11(2), 260-264 (2005).
Yu YS, Du XX, Zhou ZH, Chen YG, Li LJ: First isolation of blaIMI-2 in an Enterobacter cloacae clinical isolate from China. Antimicrob. Agents Chemother. 50(4), 1610-1611 (2006).
Bratu S, Landman D, Haag R et al.: Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165(12), 1430-1435 (2005).
Woodford N, Tierno PM Jr, Young K et al.: Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. 48(12), 4793-4799 (2004).
Yigit H, Queenan AM, Rasheed JK et al.: Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob. Agents Chemother. 47(12), 3881-3889 (2003).
Poirel L, Heritier C, Tolun V, Nordmann P: Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(1), 15-22 (2004).
Walther-Rasmussen J, Hoiby N: OXA-type carbapenemases. J. Antimicrob. Chemother. 57(3), 373-383 (2006).
Poirel L, Heritier C, Nordmann P: Chromosome-encoded ambler class D β-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. Antimicrob. Agents Chemother. 48(1), 348-351 (2004).
Brown S, Young HK, Amyes SG: Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin. Microbiol. Infect. 11(1), 15-23 (2005).
Heritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P: Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob. Agents Chemother. 49(10), 4174-4179 (2005).
Turton JF, Ward ME, Woodford N et al.: The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 258(1), 72-77 (2006).
Walsh TR, Toleman MA, Poirel L, Nordmann P: Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18(2), 306-325 (2005).
Lee K, Yum JH, Yong D et al.: Novel acquired metallo-β-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother. 49(11), 4485-4491 (2005).
Rossolini GM: Acquired metallo-β-lactamases: an increasing clinical threat. Clin. Infect. Dis. 41(11), 1557-1558 (2005).
Koradi R, Billeter M, Wuthrich K: MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14(1), 51-32 (1996).
Poirel L, Naas T, Le T-I, Karim A, Bingen E, Nordmann P: CTX-M-type extended-spectrum β-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob. Agents Chemother. 45(12), 3355-3361 (2001).
Poirel L, Naas T, Le T-I, Karim A, Bingen E, Nordmann P: CTX-M-type extended-spectrum β-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob. Agents Chemother. 45(12), 3355-3361 (2001).
Cartelle M, del Mar TM, Molina F, Moure R, Villanueva R, Bou G: High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. Antimicrob. Agents Chemother. 48(6), 2308-2313 (2004).
Alvarez M, Tran JH, Chow N, Jacoby GA: Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob. Agents Chemother. 48(2), 533-537 (2004).
Literacka E, Empel J, Baraniak A, Sadowy E, Hryniewicz W, Gniadkowski M: Four variants of the Citrobacter freundii AmpC-type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland. Antimicrob. Agents Chemother. 48(11), 4136-4143 (2004).
D'Andrea MM, Nucleo E, Luzzaro F et al.: CMY-16, a novel acquired AmpC-type β-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy. Antimicrob. Agents Chemother. 50(2), 618-624 (2006).
Song W, Kim JS, Kim HS et al.: Increasing trend in the prevalence of plasmid-mediated AmpC β-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. Diagn. Microbiol. Infect. Dis. 55(3), 219-224 (2006).
Ohana S, Leflon V, Ronco E et al.: Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC β-lactamase in a teaching hospital admitting disabled patients. Antimicrob. Agents Chemother. 49(5), 2095-2097 (2005).
Lee SH, Jeong SH, Park YM: Characterization of blaCMY-10 a novel, plasmid-encoded AmpC-type β-lactamase gene in a clinical isolate of Enterobacter aerogenes. J. Appl. Microbiol. 95(4), 744-752 (2003).
Fosse T, Giraud-Morin C, Madinier I, Labia R: Sequence analysis and biochemical characterisation of chromosomal CAV-1 (Aeromonas caviae), the parental cephalosporinase of plasmid-mediated AmpC 'FOX' cluster. FEMS Microbiol. Lett. 222(1), 93-98 (2003).
Cresti S, D'Andrea MM, Lenzi D, Tomasini B, Zani S, Rossolini GM: A new plasmid-mediated AmpC-type β-lactamase (FOX-7) produced by Klebsiella pneumoniae and Enterobacter cloacae isolates from a neonatal ICU in Italy. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 Oct-2 Nov 2004.
Lahey Clinical www.lahey.org/Studies